TY  - JOUR
AU  - Gudiol, C
AU  - Nicolae, S
AU  - Royo-Cebrecos, C
AU  - Aguilar-Guisado, M
AU  - Montero, I
AU  - Martin-Gandul, C
AU  - Perayre, M
AU  - Berbel, D
AU  - Encuentra, M
AU  - Arnan, M
AU  - Cisneros-Herreros, J M
AU  - Carratala, J
PY  - 2018
DO  - 10.1186/s13063-018-2647-y
UR  - http://hdl.handle.net/10668/12414
T2  - Trials
AB  - Catheter-related bloodstream infection (CRBSI) is one of the most frequent complications in patients with cancer who have central venous catheters (CVCs) implanted and is associated with substantial morbidity and mortality. Taurolidine is a...
LA  - en
PB  - BioMed Central Ltd.
KW  - Antibiotic lock technique
KW  - Catheter-related bloodstream infection
KW  - Central venous catheter infection
KW  - Haematological patients
KW  - Lock solution
KW  - Neutropenia
KW  - Taurolidine-citrate
KW  - Anti-Infective Agents
KW  - Antineoplastic Agents
KW  - Catheter-Related Infections
KW  - Catheterization, Central Venous
KW  - Catheters, Indwelling
KW  - Central Venous Catheters
KW  - Citrates
KW  - Device Removal
KW  - Double-Blind Method
KW  - Equivalence Trials as Topic
KW  - Hematologic Neoplasms
KW  - Humans
KW  - Multicenter Studies as Topic
KW  - Neutropenia
KW  - Prospective Studies
KW  - Risk Factors
KW  - Spain
KW  - Taurine
KW  - Thiadiazines
KW  - Time Factors
KW  - Treatment Outcome
TI  - Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
TY  - research article
VL  - 19
ER  -